Evaluation of the effect celecoxib against radiotherapy induced acute toxicities in the patients with prostate cancer compared with placebo group.
Phase 2
- Conditions
- prostate cancer.Malignant neoplasm of prostate
- Registration Number
- IRCT2016020626401N1
- Lead Sponsor
- Private
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 40
Inclusion Criteria
Histologically confirmed prostate cancer; normal levels of hemoglobin; leukocytes; platelets; creatinine; urea; bilirubine in the patients.
Exclusion criteria: clinical and radioghraphic evidence of distant metastasis before or during the trial; inability to receive celecoxib; simultaneous participation in another clinical trial; receive any other NSAIDs; patients with severe and uncontrolled cardiovascular; kidney; liver; inflammatory intestinal disease; coagulation disorders.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rinary and bowel toxicities. Timepoint: weekly. Method of measurement: questionnaire.
- Secondary Outcome Measures
Name Time Method Blood factors. Timepoint: Start and ending in radiotherapy. Method of measurement: sampling.